Covid 19 Vaccine Trials

UK investigates two adverse reactions to Pfizer jab, says people with history of serious allergic reactions shouldn't get inoculated

Professor Stephen Powis, national medical director for the National Health Service in England, said the condition of the two people who received the vaccine are recovering well

Germany COVID-19 tally rises to 10 lakh as second wave hits country; doubts emerge over vaccine

The number of COVID-19 patients in intensive care nationwide has soared from just over 360 in early October to more than 3,500 last week

Vaccine messaging faces unprecedented test with COVID-19 – success of a vaccine hinges on it

In the past, vaccine messaging has drawn on anti-polarization strategies to try building consensus around contentious issues.

AstraZeneca resumes UK trials for COVID-19 vaccine days after single recipient shows 'adverse reaction'

The trials for the coronavirus vaccine candidate, AZD1222, resumed in the UK following confirmation by the MHRA that it was safe to do so, AstraZeneca said in a statement

Uncertainty over long-term immune response has implications for efficacy of COVID-19 vaccine, say experts

In an editorial in the ICMR's, Indian Journal of Medical Research, experts also said that continued use of masks and other measures may be advocated if evidence shows a possible role of asymptomatic persons in COVID-19 transmission

Elderly, ethnic minority volunteers in COVID-19 vaccine trials vital for its success, expert says

It will be impossible to tell how well a vaccine works without recruiting a diverse range of volunteers in trials, a physician has said.

Moderna's COVID-19 vaccine helped monkeys make full recovery after SARS-CoV-2 infection

While the findings don't guarantee the vaccine will perform equally well in people, the results are considered encouraging.

Moderna, Pfizer kick off late-stage COVID-19 vaccine trials; distribution in US by end-2020 a 'stretch goal'

Moderna said it could deliver some 500 million doses a year, and possibly up to 1 billion doses per year, starting in 2021.

Regeneron begins phase III trials of REGN-COV2; here's how antibody cocktail can help COVID-19 patients

Currently, the antibody cocktail, developed by researchers at the University of Maryland School of Medicine and Regeneron, is in the phase 2 treatment trials stage

Indian pharma well-placed to develop, manufacture COVID-19 vaccine; but it must guard against rushing trials

Some experts told Firstpost that the government is willing to fast-track regulation, which is a risk they are willing to take, after completing "due protocols to check the safety of the drug"